secwatch.observer — SEC 8-K summary
======================================

Issuer:     Xenon Pharmaceuticals Inc. (XENE)
CIK:        0001582313
Form:       8-K/A
Filed at:   2025-10-17T23:59:59+00:00
Accession:  0001193125-25-242583
Event type: leadership
Sentiment:  positive
Materiality: 0.60
Item codes: 8.01, 9.01, 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Xenon names Tucker Kelly CFO with $540k salary, 225k options, 30k RSUs
----------------------------------------------------------------------

- Tucker Kelly appointed CFO effective Oct 15, 2025; replaces interim CFO Ian Mortimer who remains CEO.
- Kelly's base salary $540k; eligible for annual incentive up to 45% of base.
- Granted inducement option for 225k shares at $41.90 (Oct 15 close) vesting over 4 years.
- Granted 30k RSUs vesting 25% annually over 4 years.
- Kelly previously CFO of Deciphera, led commercial transition; will support azetukalner launch.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1582313/000119312525242583/0001193125-25-242583-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1582313/000119312525242583/xene-20251015.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-242583

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer